Cytosorbents (CTSO) Investor presentation summary

Business overview and product portfolio

• Specializes in blood purification technology for critical care and cardiac surgery, with products designed to remove toxins, cytokines, and blood thinners from blood.

• CytoSorb is CE Mark approved in Europe for cytokine, bilirubin, myoglobin, ticagrelor, and rivaroxaban removal, but not yet FDA or Health Canada approved.

• DrugSorb-ATR is an investigational device targeting perioperative bleeding in CABG patients on ticagrelor, with two FDA Breakthrough Device Designations and ongoing regulatory pursuit in the U.S.

• Over 300,000 CytoSorb devices have been used in 70+ countries, generating $37.1M in 2025 product sales with 71% gross margins.

Clinical evidence and market adoption

• Supported by extensive clinical data, including the international COSMOS registry and multiple peer-reviewed publications.

• Real-world and registry data show CytoSorb's effectiveness in reducing inflammation, bilirubin, and myoglobin, and improving outcomes in sepsis, liver failure, and rhabdomyolysis.

• DrugSorb-ATR demonstrated safety and significant reduction in severe bleeding events in CABG patients in the STAR-T pivotal trial.

• Broad physician awareness and adoption, with over 75% of surveyed clinicians using blood purification, and CytoSorb as the most common modality.

Regulatory and commercialization strategy

• CytoSorb is sold directly in Germany and nine other countries, and through distributors elsewhere.

• DrugSorb-ATR is not yet approved but is progressing through a new De Novo FDA submission, with recent positive feedback and ongoing discussions.

• STAR-T trial results published in a leading journal support DrugSorb-ATR's safety and efficacy in targeted populations.

• Strategic focus on leveraging clinical evidence, expanding indications, and restoring growth in key markets.